logo
NasdaqCM:DERM logo

Journey Medical Community

NasdaqCM:DERM Community
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Create a narrative

Community Investing Ideas

DERM logo
Journey Medical
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts

Emrosi Launch Will Expand Rosacea Treatment Options

Key Takeaways Emrosi's launch and favorable Phase III results are expected to boost revenue growth and enhance net margins through existing operations. Expansion plans and international licensing opportunities could drive significant long-term revenue and profitability growth.
View narrative
US$9.88
FV
23.6% undervalued intrinsic discount
40.13%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
7 days ago author updated this narrative